PMID- 26627265
OWN - NLM
STAT- MEDLINE
DCOM- 20160927
LR  - 20181113
IS  - 1753-9455 (Electronic)
IS  - 1753-9447 (Print)
IS  - 1753-9447 (Linking)
VI  - 10
IP  - 1
DP  - 2016 Feb
TI  - Plasma levels of neutrophil gelatinase-associated lipocalin in children with 
      heart failure.
PG  - 30-6
LID - 10.1177/1753944715619116 [doi]
AB  - INTRODUCTION: Data about plasma levels of neutrophil gelatinase-associated 
      lipocalin (NGAL) in children with heart failure (HF) are very limited. NGAL is 
      used widely as a biomarker for the diagnosis of renal injury in numerous clinical 
      studies. The aim of this study is to investigate the plasma NGAL in children with 
      HF caused by idiopathic dilated cardiomyopathy (IDCM) and its relation to the 
      severity of HF. MATERIAL AND METHODS: In a case-control study, 30 nondiabetic 
      children, aged -16 years (all have IDCM) recruited from the pediatric department 
      of our institute together with 30 healthy children were prospectively enrolled in 
      this study. Patients underwent a detailed history taking, clinical examination, 
      New York Heart Association (NYHA) class assessment and echocardiographic 
      evaluation. Plasma levels of NGAL were measured by enzyme-linked immunosorbent 
      assay. RESULTS: Plasma levels of NGAL were significantly higher in children with 
      HF compared with healthy controls (mean: 290.97 versus 144.33, p < 0.0001). The 
      relationship between NGAL and the severity of HF was investigated. However, we 
      did not find any statistically significant relationship between plasma NGAL 
      levels and indices of myocardial function. CONCLUSIONS: NGAL levels were 
      significantly increased in children with HF caused by IDCM. However, there was no 
      significant relationship between plasma NGAL levels and indices of myocardial 
      function. Future multicenter clinical studies in a large population addressing 
      the natural course of NGAL in HF and its potential as a treatment target are 
      needed in the near future.
CI  - (c) The Author(s), 2015.
FAU - Tawfeek, Mostafa S K
AU  - Tawfeek MS
AD  - Department of Pediatrics, Faculty of Medicine, Assiut University, Assiut, Egypt.
FAU - Raafat, Doaa M
AU  - Raafat DM
AD  - Department of Pediatrics, Faculty of Medicine, Assiut University, Assiut, Egypt.
FAU - Saad, Khaled
AU  - Saad K
AD  - Associate Professor of Pediatrics, Faculty of Medicine, University of Assiut, 
      Assiut 71516, Egypt khaled.ali@med.au.edu.eg ksaad8@yahoo.com.
FAU - Idriss, Naglaa K
AU  - Idriss NK
AD  - Department of Medical Biochemistry, Faculty of Medicine, Assiut University, 
      Assiut, Egypt.
FAU - Sayed, Sherif
AU  - Sayed S
AD  - Department of Anesthesiology, Faculty of Medicine, Assiut University, Assiut, 
      Egypt.
FAU - Fouad, Doaa A
AU  - Fouad DA
AD  - Department of Cardiology, Faculty of Medicine, Assiut University, Assiut, Egypt.
FAU - El-Houfey, Amira A
AU  - El-Houfey AA
AD  - Department of Community Health Nursing, Assiut University, Assiut, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20151130
PL  - England
TA  - Ther Adv Cardiovasc Dis
JT  - Therapeutic advances in cardiovascular disease
JID - 101316343
RN  - 0 (Acute-Phase Proteins)
RN  - 0 (LCN2 protein, human)
RN  - 0 (Lipocalin-2)
RN  - 0 (Lipocalins)
RN  - 0 (Proto-Oncogene Proteins)
SB  - IM
MH  - Acute-Phase Proteins
MH  - Adolescent
MH  - Cardiomyopathy, Dilated/*complications
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Heart Failure/*blood/etiology/physiopathology
MH  - Humans
MH  - Lipocalin-2
MH  - Lipocalins/*blood
MH  - Male
MH  - Prospective Studies
MH  - Proto-Oncogene Proteins/*blood
MH  - Severity of Illness Index
PMC - PMC5933603
OTO - NOTNLM
OT  - NGAL
OT  - idiopathic dilated cardiomyopathy
OT  - pediatric heart failure
COIS- Conflict of interest statement: The authors declare that there is no conflict of 
      interest.
EDAT- 2015/12/03 06:00
MHDA- 2016/09/28 06:00
PMCR- 2016/02/01
CRDT- 2015/12/03 06:00
PHST- 2015/12/03 06:00 [entrez]
PHST- 2015/12/03 06:00 [pubmed]
PHST- 2016/09/28 06:00 [medline]
PHST- 2016/02/01 00:00 [pmc-release]
AID - 1753944715619116 [pii]
AID - 10.1177_1753944715619116 [pii]
AID - 10.1177/1753944715619116 [doi]
PST - ppublish
SO  - Ther Adv Cardiovasc Dis. 2016 Feb;10(1):30-6. doi: 10.1177/1753944715619116. Epub 
      2015 Nov 30.